openPR Logo
Press release

EMDEX and ITmedicus release a new free Drug Information App on Android

07-10-2018 11:10 AM CET | Health & Medicine

Press release from: EMDEX

EMDEX App: Free Version on Android

EMDEX App: Free Version on Android

EMDEX Nigeria, in partnership with ITmedicus, is pleased to announce the launch of free EMDEX Drug Information App on Google Play Store. The iOS version will be available soon. The two companies are also working together on several other apps specifically targeting Nigeria's healthcare sector.
This Free version of EMDEX App has several unique functionalities, practice resources & tools including:
•Free CPD/CME program powered by mdBriefCase
•EMDEX RapidRx – Drug Therapy Management Newsletter
•Indication Index, etc.
EMDEX is for healthcare professionals only.
Key features:
•Drugs details (Indications, Dosage & administrations, Contraindications, Precautions & warnings, Pharmacovigilance, Adverse effects, Advice to patients, Nursing action, Drug product descriptions & Pack sizes)
•Search Drugs (Search by Brand name, Generic name or Condition)
•Drugs by Brands (A-Z brands)
•Drugs by Generics (A-Z generics)
•Drugs by Classes
•Drugs by Conditions
•Favourite Drugs (Bookmark any brand names)
•RapidRx (Drug therapy management newsletter)
Feedback (Can directly post your valuable suggestion, advice & comments)
•Advance search (Can choose different search categories)

EMDEX (Essential Medicines Index) is Nigeria’s trusted source for drug and therapeutic information published since 1991. Based on both the WHO Model Formulary and Nigeria’s Essential Drugs List, EMDEX is unique to Nigeria as it also details over 5000 drug products approved for use in the country

6040 Montevideo Road
Unit 48

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release EMDEX and ITmedicus release a new free Drug Information App on Android here

News-ID: 1116796 • Views: 343

More Releases from EMDEX

07-24-2018 | Health & Medicine
EMDEX
EMDEX announces Partnership with Pharmécrit
EMDEX Limited is pleased to announce a new strategic partnership with Pharmécrit effective March 5, 2018. This relationship is established with a sole objective of producing high quality, evidence-based, and up-to-date information about drugs and their therapeutic applications. This will be made available through EMDEX publications to all healthcare professionals in Nigeria, Africa, and the rest of the world. Pharmécrit, a medical communications company, is the new leading medical content contributor
11-06-2017 | Health & Medicine
EMDEX
May & Baker and Others Sponsor 2017 Annual Pharmacists Conference in Nigeria
Umuahia, the capital city of Abia State in southeastern Nigeria, will be hosting over 5000 pharmacists at the 2017th edition of PSN national conference. There will also be exhibitions by pharmaceutical manufacturers and importers from within and outside the country. This annual event is usually the largest gathering of pharmacists and pharmaceutical companies in Africa. LAGOS, Nigeria. November 5, 2017 - The 90th Annual National Conference of the PHARMACEUTICAL SOCIETY OF
11-03-2017 | Health & Medicine
EMDEX
Pemason Pharma Sponsors Drug Information Publication - EMDEX 2018-2019 Edition
Publication of drug information is a costly operation, made more challenging in a harsh economic and resource-limited setting like the sub-Saharan Africa. To sustain its yearly updates and digitize the print editions, EMDEX needed a lifeline in form of sponsorship. Pemason, Nigeria’s leading pharmaceutical firm, promptly said yes to the initiative. The outcome is the onset of a unique partnership that can potentially change the face of healthcare in the

All 4 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning